{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:13:32Z","timestamp":1777914812790,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11302-026-10142-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:11:36Z","timestamp":1773295896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phenolic compounds and chemotherapeutic agents differentially regulate P2X receptor subtypes in malignant melanoma"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2884-4753","authenticated-orcid":false,"given":"Serkan","family":"Sen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5187-378X","authenticated-orcid":false,"given":"Sefa","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"4","key":"10142_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","volume":"82","author":"RA North","year":"2002","unstructured":"North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82(4):1013\u20131067","journal-title":"Physiol Rev"},{"issue":"3","key":"10142_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00441-005-1149-x","volume":"321","author":"N White","year":"2005","unstructured":"White N, Butler PE, Burnstock G (2005) Human melanomas express functional P2X7 receptors. Cell Tissue Res 321(3):411\u2013418","journal-title":"Cell Tissue Res"},{"key":"10142_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00793","volume":"11","author":"R Lara","year":"2020","unstructured":"Lara R, Adinolfi E, Harwood CA, Philpott M, Barden JA, Di Virgilio F, McNulty S (2020) P2X7 in cancer: from molecular mechanisms to therapeutics. Front Pharmacol 11:793","journal-title":"Front Pharmacol"},{"key":"10142_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2016.00048","volume":"3","author":"Z Harris","year":"2016","unstructured":"Harris Z, Donovan MG, Branco GM, Limesand KH, Burd R (2016) Quercetin as an emerging anti-melanoma agent: a four-focus area therapeutic development strategy. Front Nutr 3:48","journal-title":"Front Nutr"},{"issue":"12","key":"10142_CR5","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.21873\/anticanres.17356","volume":"44","author":"M Kanai","year":"2024","unstructured":"Kanai M, Shinagawa A, Ota M, Virgona N, Yano T (2024) Resveratrol can differentiate human melanoma stem-like cells from spheroids treated with all-trans retinoic acid. Anticancer Res 44(12):5283\u20135292","journal-title":"Anticancer Res"},{"issue":"9","key":"10142_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27092665","volume":"27","author":"SA Almatroodi","year":"2022","unstructured":"Almatroodi SA, A Alsahli M, SM Aljohani A, Alhumaydhi FA, Babiker AY, Khan AA, Rahmani AH (2022) Potential therapeutic targets of resveratrol, a plant polyphenol, and its role in the therapy of various types of cancer. Molecules 27(9):2665","journal-title":"Molecules"},{"issue":"11","key":"10142_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119196","volume":"24","author":"R Sluyter","year":"2023","unstructured":"Sluyter R (2023) Purinergic signalling in physiology and pathophysiology. Int J Mol Sci 24(11):9196","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10142_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.molonc.2012.09.005","volume":"6","author":"SS Nair","year":"2012","unstructured":"Nair SS, Kumar R (2012) Chromatin remodeling in cancer: a gateway to regulate gene transcription. Mol Oncol 6(6):611\u2013619","journal-title":"Mol Oncol"},{"issue":"12","key":"10142_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04378-0","volume":"12","author":"A Pegoraro","year":"2021","unstructured":"Pegoraro A, De Marchi E, Ferracin M, Orioli E, Zanoni M, Bassi C, Adinolfi E (2021) P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death Dis 12(12):1088","journal-title":"Cell Death Dis"},{"issue":"11","key":"10142_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2174\/011570159X355614250130100132","volume":"23","author":"MC Bianchini","year":"2025","unstructured":"Bianchini MC, Franscescon F, Soares AA, Ansolin V, Pretto KP, da Vieira Cunha ML, de Resen e Silva DT (2025) Potential benefits of quercetin through P2X7 modulation against neuroinflammation in Alzheimer\u2019s disease. Curr Neuropharmacol 23(11):1367\u20131379","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"10142_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040656","volume":"61","author":"T Hoinoiu","year":"2025","unstructured":"Hoinoiu T, Dumitrascu V, Pit D, Schipor DA, Jabri-Tabrizi M, Hoinoiu B, Petreu\u0219 DE, Seiman C (2025) Quercetin as a potential therapeutic agent for malignant melanoma-a review of current evidence and future directions. Medicina (Kaunas) 61(4):656","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10142_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12020407","volume":"12","author":"E Isacescu","year":"2023","unstructured":"Isacescu E, Chiroi P, Zanoaga O, Nutu A, Budisan L, Pirlog R, Atanasov AG, Berindan-Neagoe I (2023) Melanoma cellular signaling transduction pathways targeted by polyphenols action mechanisms. Antioxidants (Basel) 12(2):407","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"10142_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11302-020-09760-9","volume":"17","author":"JB de Araujo","year":"2021","unstructured":"de Araujo JB, Kerkhoff VV, de Oliveira Maciel SFV, de Resen e Silva DT (2021) Targeting the purinergic pathway in breast cancer and its therapeutic applications. Purinergic Signal 17(2):179\u2013200","journal-title":"Purinergic Signal"},{"key":"10142_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1058371","volume":"13","author":"J Kaur","year":"2023","unstructured":"Kaur J, Dora S (2023) Purinergic signaling: diverse effects and therapeutic potential in cancer. Front Oncol 13:1058371","journal-title":"Front Oncol"},{"issue":"1","key":"10142_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11010-009-0288-x","volume":"337","author":"EA Orellano","year":"2010","unstructured":"Orellano EA, Rivera OJ, Chevres M, Chorna NE, Gonz\u00e1lez FA (2010) Inhibition of neuronal cell death after retinoic acid-induced down-regulation of P2X7 nucleotide receptor expression. Mol Cell Biochem 337(1):83\u201399","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"10142_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11302-005-7331-5","volume":"2","author":"K Fujishita","year":"2006","unstructured":"Fujishita K, Koizumi S, Inoue K (2006) Upregulation of P2Y2 receptors by retinoids in normal human epidermal keratinocytes. Purinergic Signal 2(3):491\u2013498","journal-title":"Purinergic Signal"},{"issue":"7","key":"10142_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ph18070950","volume":"18","author":"BF Bissacotti","year":"2025","unstructured":"Bissacotti BF, da Silveira MV, Assmann CE, Copetti PM, Santos AFD, Fagan SB, da Silva AS (2025) Resveratrol alleviates inflammatory response through P2X7\/NLRP3 signaling pathway: in silico and in vitro evidence from activated microglia. Pharmaceuticals 18(7):950","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10142_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11302-017-9593-0","volume":"14","author":"G Burnstock","year":"2018","unstructured":"Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal 14(1):1\u201318","journal-title":"Purinergic Signal"},{"key":"10142_CR19","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1186\/1744-8069-10-53","volume":"10","author":"R Ochi-Ishi","year":"2014","unstructured":"Ochi-Ishi R, Nagata K, Inoue T, Tozaki-Saitoh H, Tsuda M, Inoue K (2014) Involvement of the chemokine CCL3 and the purinoceptor p2\u00d7 7 in the spinal cord in paclitaxel-induced mechanical allodynia. Mol Pain 10:1744\u20138069","journal-title":"Mol Pain"},{"key":"10142_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109584","volume":"236","author":"C Mei","year":"2023","unstructured":"Mei C, Pan C, Xu L, Miao M, Lu Q, Yu Y, Lin P, Wu W, Ni F, Gao Y, Xu Y, Xu J, Chen X (2023) Trimethoxyflavanone relieves Paclitaxel-induced neuropathic pain via inhibiting expression and activation of P2X7 and production of CGRP in mice. Neuropharmacology 236:109584","journal-title":"Neuropharmacology"},{"key":"10142_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejphar.2017.08.011","volume":"814","author":"H Sandhu","year":"2017","unstructured":"Sandhu H, Cooper S, Hussain A, Mee C, Maddock H (2017) Attenuation of sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation. Eur J Pharmacol 814:95\u2013105","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10142_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.5815","volume":"256","author":"JP Maynard","year":"2022","unstructured":"Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB, Joshu CE, Lotan TL, De Marzo AM, Sfanos KS (2022) P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. J Pathol 256(2):149\u2013163","journal-title":"J Pathol"},{"issue":"4","key":"10142_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11302-013-9372-5","volume":"9","author":"G Burnstock","year":"2013","unstructured":"Burnstock G, Di Virgilio F (2013) Purinergic signalling and cancer. Purinergic Signal 9(4):491\u2013540","journal-title":"Purinergic Signal"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10142-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10142-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10142-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:02:02Z","timestamp":1777654922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-026-10142-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10142"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10142-w","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of \u0131nterest"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"27"}}